Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

  • Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by Yelena Y. Janjigian, M.D., Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, and Lead Investigator for the EDGE-Gastric study
  • Data from ARC-9 evaluating an etrumadenant plus zimberelimab-based treatment combination in third-line metastatic colorectal cancer will be presented in an oral presentation by Zev A. Wainberg, M.D., MSc, Co-Director UCLA Gastrointestinal Oncology Program, and Lead Investigator for the ARC-9 study
  • Trial in Progress (TIP) poster for VELOCITY-Lung Substudy-03, a Phase 2 study of perioperative domvanalimab plus zimberelimab and chemotherapy in patients with resectable Stage II-III non-small cell lung cancer

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2024. The selected abstracts presented in partnership with Gilead Sciences provide strong support for the companies’ portfolio of investigational medicines across multiple types of cancer, including lung, upper GI and colorectal cancer.

“We will have two oral presentations for Phase 2 studies that highlight the potential for novel immuno-oncology mechanisms and combinations in gastrointestinal cancers,” said Terry Rosen, Ph.D., chief executive officer of Arcus. “The EDGE-Gastric presentation will include the median progression-free survival (PFS) data for our Fc-silent anti-TIGIT antibody in combination with zimberelimab and chemotherapy in upper GI cancers, the same setting as our STAR-221 Phase 3 study. The ARC-9 presentation will include randomized PFS and overall survival data for an etrumadenant (our adenosine receptor antagonist)-based combination therapy versus regorafenib, an approved standard of care in third-line colorectal cancer.”

Three Accepted Abstracts Will Be Presented



Abstract Number

Session Type &


Session Date

& Time

Domvanalimab (Fc-silent anti-TIGIT monoclonal antibody) plus Zimberelimab (anti-PD-1 antibody)


Updates on Abstract 433248: EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.


ASCO Plenary Series: Rapid Abstract Updates


12:30 PM –

1:30 PM CT

VELOCITY-Lung Substudy-03 TIP

VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).


Poster Session – Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers


1:30 PM –

4:30 PM CT

Etrumadenant (A2a/A2b receptor antagonist)


ARC-9: A Randomized Study to Evaluate Etrumadenant-Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC)


Gastrointestinal Cancer—Colorectal and Anal: Oral Abstract Session


8:00 AM –

11:00 AM CT

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit

Domvanalimab, zimberelimab and etrumadenant are investigational molecules. Neither Gilead nor Arcus has received approval from any regulatory authority for any use of these molecules, and their safety and efficacy for the treatment of gastrointestinal and lung cancers have not been established.

The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.


Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.